Monday 17 November 2008, The international Ludwig Institute for Cancer Research (LICR) announced today that one of its spin-off companies, Life Science Pharmaceuticals, has licensed its lead cancer therapy candidate to pharmaceutical company Abbott.

Friday 15 August 2008, Investigators from the Melbourne Center of the international Ludwig Institute For Cancer Research (LICR) and Pacific Edge Biotchnology Ltd today reported that they have developed a test to predict whether a patient will progress rapidly from Stage III melanoma to metastatic Stage IV cancer and death.

July 16, 2008. The Melanoma Research Alliance (MRA), a new public charity based in Washington D.C., USA, recently awarded 8 million USD in grants to individual scientist and research teams to support innovative melanoma research worldwide. An international team headed by Prof. Jonathan Cebon (LICR Melbourne Centre) received one of six Team Science Awards of 1million USD. The award will be used to explore immune targeting of melanoma stem cells. The team also includes Drs. Otavia Caballero (LICR New York Branch), Winston Hide (LICR Affiliate, South African National Bioinformatics Institute, South Africa), and Michael Berridge (Malaghan Institute for Medical Research, New Zealand)

Friday 8 June 2007, The LICR Brain Cancer Initiative held its first meeting in New York on June 8th and 9th. LICR has a strong history in glioblastoma research, in particular, and there was great enthusiasm among the 34 participants from six Branches, the Melbourne Center, the Ludwig Center at Johns Hopkins and two Affiliates.

The Time magazine issue - 'The Most Influential People in the World' May 14th, 2007 -included Mr. Ludwig in it's list of "Power Givers - Philanthropists of Yore.' The list of 11 such philanthropists also included Messrs. John Pierpont Morgan, John D. Rockefeller, Andrew Carnegie, Alfred Nobel, Cecil Rhodes and Joseph Pulitzer.

Friday 9 June 2006, Dr Ken Pang, from the Ludwig Institute For Cancer Research in Heidelberg, whose research into the role of "junk DNA" reveals that it may in fact be essential in helping us understand how the human genome works, and promises to significantly influence the future practice of medicine.

Monday 5 June 2006, The Ludwig Institute For Cancer Research (LICR) and Life Science Pharmaceuticals (LSP) today announced the results of the first clinical trial of monoclonal antibody (mAb) 806, which demonstrate that 806 specifically targets epidermal growth factor receptor (EGFR) on a wide range of tumor types but has no uptake by normal tissues. This result is markedly different to other mAbs, which target wild-type (wt) EGFR on normal tissues.

Monday 5 June 2006, London, UK & New York, US-GlaxoSmithKline (NYSE and LSE: GSK) and the international Ludwig Institute For Cancer Research (LICR) today announce they have entered into an agreement whereby GSK has licensed a substantial portfolio of tumor-specific antigens from LICR. The licensing agreement follows a long-standing collaboration between both parties on GSK's investigational MAGE-A3 Antigen Specific Cancer Immunotherapeutic (ASCI) in Non-Small Cell Lung Cancer (NSCLC).

Sunday 30 April 2006, (Melbourne, New York, Helsinki) - The Ludwig Institute For Cancer Research ("LICR") together with Circadian Technologies Limited (ASX: CIR) and Licentia Ltd, the commercial arm of the University of Helsinki, has announced the formation of a new company, Vegenics Ltd. Vegenics will develop and commercialise LICR and Licentia intellectual property and technology around the inhibition of two vascular endothelial growth factors (VEGFs) and the VEGF receptor-3, molecules required for angiogenesis and lymphangiogenesis, which allow tumors to grow and cancer to spread. The cancer therapy, Avastin®, inhibits one member of the VEGF family and in 2005 earned Genentech ~US$1.1 billion.